BIO CEO & Investor Conference Programming Announced

WASHINGTON–(BUSINESS WIRE)– The Biotechnology
Innovation Organization (BIO) today announced programming for the 19^th
annual BIO
CEO & Investor Conference. Held February 13-14 at the Waldorf
Astoria in New York, the annual conference provides an environment for
investors, analysts, industry executives and others to discover trends
in life sciences, network with peers and potential partners and explore
investment opportunities. Established and emerging publicly traded and
select private biotech companies are the focus of the event.

“The best way to find investment opportunities is through education,
networking and one-on-one partnering—all of which happens at BIO’s CEO &
Investor Conference. We offer an event designed to propel partnerships
that lead to medical breakthroughs never imagined possible,” said BIO
President and CEO Jim Greenwood. “This annual conference attracts
industry analysts, investment bankers and senior biotechnology
executives – all in search of opportunities that will help them
accomplish their objectives. We have lined up fireside chats hosted by
industry leaders, company presentations from innovative firms, panel
discussions on industry trends and individual partnering meetings
between biopharma executives and investors. This event again offers
enormous opportunities for companies and investors to build new and
productive partnerships.”

Two industry leaders are slated for Fireside
Chats and more will be announced in the near future. Those scheduled
include:

• Dr. Giovanni Caforio, Chief Executive Officer (CEO) of
  Bristol-Myers Squibb. Caforio has been with the company since 2000,
  assuming the role of CEO in May, 2015. He has a long history of
  leadership positions in the biotech industry.
• Dr. Tony Coles, CEO of Yumanity Therapeutics. Coles is a
  founding investor in the company and also serves as chairman and chief
  executive officer of TRATE Enterprises, LLC. In addition to holding
  leadership positions within oncology, internal medicine and cardiology
  sectors, Coles was named to the NIH working group tasked with charting
  the course for President Obama’s Precision Medicine Initiative.

More than 175
company presentations by senior-level executives are expected this
year – each designed to showcase their respective product pipelines, R&D
activities, and investment goals before an audience of investors,
research analysts, investment bankers and industry
executives. Educational panel discussions around both therapeutics and
business topics are also planned.

Discounted rates for early registration will end 5:00 PM EST today.

Advance media
registration is available for qualified reporters working full time
for print, broadcast and web publications with valid press credentials.

About BIO

BIO is the world’s largest trade association representing biotechnology
companies, academic institutions, state biotechnology centers and
related organizations across the United States and in more than 30 other
nations. BIO members are involved in the research and development of
innovative healthcare, agricultural, industrial and environmental
biotechnology products. BIO also produces the BIO
International Convention, the world’s largest gathering of the
biotechnology industry, along with industry-leading investor and
partnering meetings held around the world. BIOtechNOW is
BIO’s blog chronicling “innovations transforming our world” and the BIO
Newsletter is the organization’s bi-weekly email newsletter. Subscribe
to the BIO Newsletter.

Upcoming BIO Events

BIO
CEO & Investor Conference
February 13-14, 2017
New York

BIO
Asia International Conference
March 14-15, 2017
Tokyo,
Japan

BIO-Europe
Spring Conference
March 20-22, 2017
Barcelona, Spain

Image may be NSFW.
Clik here to view.

View source version on businesswire.com: http://www.businesswire.com/news/home/20161215005943/en/